Fintel reports that on May 22, 2023, Goldman Sachs maintained coverage of Krystal Biotech (NASDAQ:KRYS) with a Buy recommendation.

Analyst Price Forecast Suggests 1.71% Downside

As of May 11, 2023, the average one-year price target for Krystal Biotech is 115.52. The forecasts range from a low of 101.00 to a high of $141.75. The average price target represents a decrease of 1.71% from its latest reported closing price of 117.53.

See our leaderboard of companies with the largest price target upside.

The projected annual revenue for Krystal Biotech is 42MM. The projected annual non-GAAP EPS is -4.84.

What is the Fund Sentiment?

There are 369 funds or institutions reporting positions in Krystal Biotech. This is an increase of 11 owner(s) or 3.07% in the last quarter. Average portfolio weight of all funds dedicated to KRYS is 0.23%, a decrease of 9.77%. Total shares owned by institutions increased in the last three months by 0.86% to 23,185K shares. The put/call ratio of KRYS is 0.38, indicating a bullish outlook.

What are Other Shareholders Doing?

FBIOX – Biotechnology Portfolio holds 2,098K shares representing 8.13% ownership of the company. In it’s prior filing, the firm reported owning 2,106K shares, representing a decrease of 0.39%. The firm increased its portfolio allocation in KRYS by 12.95% over the last quarter.

Redmile Group holds 1,913K shares representing 7.42% ownership of the company. In it’s prior filing, the firm reported owning 1,897K shares, representing an increase of 0.87%. The firm increased its portfolio allocation in KRYS by 8.14% over the last quarter.

Avoro Capital Advisors holds 1,750K shares representing 6.78% ownership of the company. In it’s prior filing, the firm reported owning 1,410K shares, representing an increase of 19.43%. The firm increased its portfolio allocation in KRYS by 24.43% over the last quarter.

Lord, Abbett & Co. holds 961K shares representing 3.73% ownership of the company. In it’s prior filing, the firm reported owning 1,278K shares, representing a decrease of 32.96%. The firm decreased its portfolio allocation in KRYS by 23.37% over the last quarter.

Frazier Life Sciences Management holds 945K shares representing 3.66% ownership of the company. In it’s prior filing, the firm reported owning 1,000K shares, representing a decrease of 5.75%. The firm increased its portfolio allocation in KRYS by 111,194.68% over the last quarter.

Krystal Biotech Background Information
(This description is provided by the company.)

Krystal Biotech, Inc. is a pivotal-stage gene therapy company leveraging its novel, redosable gene therapy platform and in-house manufacturing capabilities to develop therapies to treat serious rare diseases.

Key filings for this company:

• UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

This article originally appeared on Fintel

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.